News headlines about Obalon Therptcs (NASDAQ:OBLN) have been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Obalon Therptcs earned a news impact score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.5317250381399 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Obalon Therptcs (NASDAQ:OBLN) opened at 9.60 on Wednesday. The stock’s market capitalization is $161.51 million. The stock has a 50 day moving average of $9.57 and a 200-day moving average of $9.24. Obalon Therptcs has a 52 week low of $8.27 and a 52 week high of $15.88.
Obalon Therptcs (NASDAQ:OBLN) last posted its earnings results on Wednesday, August 2nd. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). The firm had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $1.77 million. Obalon Therptcs had a negative net margin of 566.87% and a negative return on equity of 108.07%. On average, equities research analysts expect that Obalon Therptcs will post ($1.86) EPS for the current year.
A number of analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Obalon Therptcs from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Northland Securities assumed coverage on shares of Obalon Therptcs in a research note on Wednesday, June 21st. They issued an “under perform” rating and a $6.00 price objective for the company. Canaccord Genuity reissued a “buy” rating on shares of Obalon Therptcs in a research note on Thursday, May 18th. ValuEngine raised shares of Obalon Therptcs from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, UBS AG reissued a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Obalon Therptcs in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $15.17.
TRADEMARK VIOLATION WARNING: “Obalon Therptcs (OBLN) Getting Somewhat Favorable Media Coverage, Report Finds” was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/09/13/obalon-therptcs-obln-getting-somewhat-favorable-media-coverage-report-finds.html.
About Obalon Therptcs
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.